Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma

Multiple myeloma is a malignant disorder characterized by bone marrow proliferation of plasma cells and by overproduction of monoclonal immunoglobulin detectable in the sera (M-spike). Anemia is a common complication of multiple myeloma, but the underlying pathophysiological mechanisms have not been completely elucidated. We aimed to identify the different determinants of anemia using the Vk*MYC mouse, which spontaneously develops an indolent bone marrow localized disease with aging. Affected Vk*MYC mice develop a mild normochromic normocytic anemia. We excluded the possibility that anemia results from defective erythropoietin production, inflammation or increased hepcidin expression. Mature erythroid precursors are reduced in Vk*MYC bone marrow compared with wild-type. Malignant plasma cells express the apoptogenic receptor Fas ligand and, accordingly, active caspase 8 is detected in maturing erythroblasts. Systemic iron homeostasis is not compromised in Vk*MYC animals, but high expression of the iron importer CD71 by bone marrow plasma cells and iron accumulation in bone marrow macrophages suggest that iron competition takes place in the local multiple myeloma microenvironment, which might contribute to anemia. In conclusion, the mild anemia of the Vk*MYC model is mainly related to the local effect of the bone marrow malignant clone in the absence of an overt inflammatory status. We suggest that this reproduces the initial events triggering anemia in patients.

[1]  S. Rivella The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. , 2012, Blood reviews.

[2]  A. Trumpp,et al.  Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. , 2012, Blood.

[3]  U. Testa,et al.  Apoptotic mechanisms in the control of erythropoiesis , 2004, Leukemia.

[4]  L. De Franceschi,et al.  Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis. , 2013, Blood.

[5]  Tomas Ganz,et al.  Hepcidin and iron regulation, 10 years later. , 2011, Blood.

[6]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.

[7]  M. Oukka,et al.  Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Weiss Iron metabolism in the anemia of chronic disease. , 2009, Biochimica et biophysica acta.

[9]  Angela C. Colmone,et al.  Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells , 2008, Science.

[10]  Elizabeta Nemeth,et al.  In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. , 2010, Blood.

[11]  M. Lidonnici,et al.  Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. , 2012, Blood.

[12]  G. Tonon,et al.  Iron increases the susceptibility of multiple myeloma cells to bortezomib , 2013, Haematologica.

[13]  H. Niederegger,et al.  Autocrine formation of hepcidin induces iron retention in human monocytes. , 2008, Blood.

[14]  Donald Limbrick,et al.  Mouse Models of Anemia of Cancer , 2014, PloS one.

[15]  P. L. Bergsagel,et al.  Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. , 2012, Blood.

[16]  T. Ganz,et al.  Involvement of Hepcidin in the Anemia of Multiple Myeloma , 2008, Clinical Cancer Research.

[17]  E. Fung,et al.  Manipulation of the hepcidin pathway for therapeutic purposes , 2013, Haematologica.

[18]  P. L. Bergsagel,et al.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. , 2008, Cancer cell.

[19]  T. Ganz,et al.  Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response , 2009, American journal of hematology.

[20]  F. Dammacco,et al.  Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. , 2001, Blood.

[21]  F. Dammacco,et al.  Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. , 2002, Blood.

[22]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.

[23]  Kou-Juey Wu,et al.  Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. , 1999, Science.

[24]  S. Modoni,et al.  Clinical results of recombinant erythropoietin in transfusion‐dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis , 1997, European journal of haematology.

[25]  D. Cella,et al.  The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. , 1997, Seminars in hematology.

[26]  T. Hagve,et al.  [Anemia of chronic disease]. , 2017, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.